8-K: Oncology Institute Reports Strong Q4, Targets 2026 Profitability

The Oncology Institute, Inc. announced improved Q4 and full-year 2025 financial results, driven by capitated care expansion, and projects positive Adjusted EBITDA for 2026.

Summary

• The Oncology Institute reported consolidated revenue of $142.0 million for Q4 2025, a 41.6% increase compared to Q4 2024.
• Gross profit for Q4 2025 increased by 55.2% to $22.7 million.
• Net loss for Q4 2025 improved to $(7.5) million from $(13.2) million in Q4 2024.
• Adjusted EBITDA for Q4 2025 was positive at $147 thousand, a significant improvement from $(7.8) million in Q4 2024.
• For the full year 2025, consolidated revenue grew 27.8% to $502.7 million.
• Full year 2025 gross profit increased 41.6% to $76.4 million.
• Net loss for the full year 2025 improved to $(60.6) million from $(64.7) million in 2024.
• Adjusted EBITDA for the full year 2025 improved to $(12.4) million from $(35.7) million in 2024.
• Cash and cash equivalents stood at $33.6 million as of December 31, 2025.
• The company initiated 9 new capitated contracts in 2025 across CA, FL, and NV, adding approximately 260,000 lives under management.
• Guidance for fiscal year 2026 includes revenue of $630 to $650 million, gross profit of $97 to $107 million, and Adjusted EBITDA of $0 to $9 million.
• The company expects approximately $150 million in capitated revenue in 2026 and anticipates Q1 2026 Adjusted EBITDA to be between $(1) million and $(3) million due to seasonality.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, demonstrating significant operational improvements and a clear path towards profitability, particularly with the achievement of positive Q4 Adjusted EBITDA and positive 2026 guidance, despite ongoing net losses.

Positives

• Consolidated revenue increased significantly by 41.6% in Q4 2025 to $142.0 million and by 27.8% for the full year 2025 to $502.7 million.
• Gross profit saw substantial growth, up 55.2% in Q4 2025 to $22.7 million and 41.6% for the full year 2025 to $76.4 million.
• Net loss improved in Q4 2025 to $(7.5) million from $(13.2) million, and for the full year 2025 to $(60.6) million from $(64.7) million.
• Achieved positive Adjusted EBITDA of $147 thousand in Q4 2025, a significant turnaround from $(7.8) million in Q4 2024.
• Full year 2025 Adjusted EBITDA improved substantially to $(12.4) million from $(35.7) million in 2024.
• Cash flow from operations in Q4 2025 was positive at approximately $3.2 million, reflecting disciplined working capital management.
• Expanded capitated footprint by initiating 9 new contracts in 2025, adding approximately 260,000 additional lives under management.
• Ramped capitation partnership with Elevance in Florida, with plans to more than double the current partnership in 2026.
• Initiated new capitation agreements with Humana and CarePlus in Florida, expanding payor partnerships and adding approximately 22,000 additional MA lives.
• Reaffirmed expectation to achieve full-year positive Adjusted EBITDA in 2026, with guidance between $0 and $9 million.

Negatives

• The company reported a net loss of $(7.5) million for Q4 2025 and $(60.6) million for the full year 2025, indicating continued unprofitability on a GAAP basis.
• Basic and diluted loss per share remained negative at $(0.06) for Q4 2025 and $(0.54) for the full year 2025.
• Cash and cash equivalents decreased from $49.669 million at December 31, 2024, to $33.565 million at December 31, 2025.
• Stockholders' equity shifted from a positive $3.589 million at December 31, 2024, to a deficit of $(15.720) million at December 31, 2025.
• Free Cash Flow for the full year 2025 remained negative at $(23.873) million, although it improved from $(25.829) million in 2024.
• Anticipates Q1 2026 Adjusted EBITDA to be negative, between $(1) million and $(3) million, due to seasonality with patient deductibles resetting and lagged pharmaceutical reimbursement adjustments.

Risks

• The accuracy of the assumptions underlying the 2026 full fiscal year outlook.
• The outcome of judicial and administrative proceedings or investigations that could interrupt or limit operations, result in adverse judgments, settlements or fines, and create negative publicity.
• Changes in patient or payors' preferences, prospects, and the competitive conditions prevailing in the healthcare sector.
• Failure to continue to meet stock exchange listing standards.
• The impact of a cybersecurity incident affecting a software provider on the company's business.
• The impact of the war in Iran.
• Unanticipated developments in the business or changes in the operating or economic environment.
• The impact of the company's acquisitions, dispositions, or financings.
• A largely stable global market is assumed, which would likely be negatively impacted if recent tariff rate increases and exchange rate changes persist and adversely affect world trade.

Future Outlook

The Oncology Institute provided guidance for fiscal year 2026, projecting revenue between $630 million and $650 million, gross profit between $97 million and $107 million, and Adjusted EBITDA between $0 and $9 million, indicating an expectation for full-year positive Adjusted EBITDA. The company anticipates approximately $150 million in capitated revenue for 2026. First quarter Adjusted EBITDA is expected to be between $(1) million and $(3) million due to seasonality, including patient deductible resets and lagged pharmaceutical reimbursement adjustments. Specialty pharmacy revenue is assumed to maintain a run-rate of approximately $27 million per month from the second half of 2025, with an additional 3-5% growth from new capitation lives.

Management Comments

• "2025 was an incredibly productive year for The Oncology Institute. Our unwavering commitment to delivering high-quality oncology care drove meaningful progress across our business, with continued expansion of our capitated care model through delegated arrangements serving as the primary catalyst."
• "These arrangements allow us to manage the oncology benefit more comprehensively, while aligning incentives with our payor partners and delivering quality clinical outcomes to the patients we serve."
• "Our growing scale, steady working capital management, and clinical pathways, all contributed to the fourth quarter marking a significant milestone on our path to becoming a profitable public company."
• "Looking ahead to 2026, we are acutely focused on execution, enhancing our scale, and delivering profitable growth."
• "Key initiatives include continuing to expand our delegated capitated model, launching a proprietary network provider portal to strengthen engagement with our affiliated partners, and adding expertise to our board with recent appointments like Mark Stolper and Kim Tzoumakas."
• "Based on the momentum from our fourth quarter, we are reaffirming our expectation to achieve full-year positive Adjusted EBITDA in 2026. We remain well-positioned to expand payor partnerships and deliver sustainable growth as we execute on our strategic goals."

Industry Context

StockSavvy.ai notes that TOI's focus on value-based care and the expansion of its capitated care model align with a broader industry trend in healthcare, particularly in oncology, towards risk-sharing arrangements and outcomes-based reimbursement. This shift aims to control rising healthcare costs while improving patient outcomes and care coordination, positioning TOI to capitalize on evolving payor strategies and demand for integrated, efficient cancer care.

Management Changes

Stakeholder Impact

• Shareholders: Potential for increased shareholder value if the company achieves sustained profitability and positive free cash flow as guided, but current dilution from ongoing capital raising activities.
• Patients: Continued expansion of value-based care models and clinical pathways suggests improved access to high-quality, coordinated oncology care.
• Payors: Strengthening partnerships through new and expanded capitated contracts indicates better alignment of incentives and potential for more efficient care delivery.
• Employees: Growth and expansion of the company's footprint and services could lead to job stability and opportunities within the organization.

Next Steps

• Continue to expand the delegated capitated model.
• Launch a proprietary network provider portal to strengthen engagement with affiliated partners.
• Continue expansion of the Elevance partnership across Florida in 2026, aiming to more than double the current partnership.
• Achieve full-year positive Adjusted EBITDA in 2026.
• Expand payor partnerships and deliver sustainable growth.

Key Dates

Recommendation

The company demonstrated strong operational improvements in Q4 2025, achieving positive Adjusted EBITDA and significantly reducing its net loss, with a clear path to full-year positive Adjusted EBITDA in 2026. However, the company still reported a net loss and negative free cash flow for the full year 2025, and its stockholders' equity is in a deficit. While the strategic direction and operational execution are positive, the financial position still carries risks, warranting a hold until sustained profitability and positive free cash flow are consistently demonstrated.

Keywords

Oncology, Healthcare, Value-based care, Cancer treatment, Financial results, Q4 2025, Full Year 2025, 2026 guidance, Adjusted EBITDA, Capitated contracts, NASDAQ: TOI, Specialty pharmacy